Samuel Collins

Samuel Collins is the Chief Medical Officer at Actio Biosciences, Inc. Samuel previously held positions at Edgewise Therapeutics and Pfizer, where Samuel led clinical development programs for rare muscle disorders and achondroplasia. With a background in pediatrics, respiratory medicine, and rare disease research, Samuel has extensive experience in medical leadership, regulatory interactions, and patient advocacy within the pharmaceutical industry. Samuel holds multiple degrees in medicine, a Ph.D., an MBA, and additional certifications in pharmaceutical medicine and medical education.